Coronary Access After TAVR: A Potential Problem Ahead

Coronary cannulation after transcatheter aortic valve replacement (TAVR) was unsuccessful in almost 10% of patients. This problem occurred almost exclusively in those who received a self-expanding valve.

coronarias post TAVI

This study, recently published in JACC Cardiovasc Interv., was sought to investigate the feasibility of coronary ostia access after TAVR and describe potential predictors of coronary access impairment.

RE-ACCESS (Reobtain Coronary Ostia Cannulation Beyond Transcatheter Aortic Valve Stent) was a prospective, register-based study that enrolled consecutive patients who underwent TAVR using commercially available devices.

All patients underwent coronary angiography before and after TAVR.

Among 300 patients enrolled in the RE-ACCESS study from 2018 to 2020, about 23 (7.7%) could not be selectively catheterized after TAVR.


Read also: ISCHEMIA: New Analysis Might Change Study Outcome Interpretation.


Out of said 23 patients, 22 had received the Evolut R/PRO valve (17.9% vs. 0.4%; p < 0.01).

The multivariate analysis showed that, for the self-expanding prosthesis (odds ratio [OR]: 29.6; 95% confidence interval: 2.6 to 335.0; p < 0.01), the prosthesis height-sinus of Valsalva relation (p < 0.01) and implantation depth (OR: 1.1 per each extra 1 mm in depth; p < 0.01) were independent predictors of unsuccessful selective coronary cannulation.

A model taking into account these factors could predict with very high accuracy the level of access difficulty (area under the curve: 0.94; p < 0.01).

Conclusion

After TAVR, it is impossible to perform selective coronary catheterization in 7.7% of patients. This difficulty appears almost exclusively in patients who received the Evolut prosthesis.

Original Title: Coronary Cannulation After Transcatheter Aortic Valve Replacement. The RE-ACCESS Study.

Reference: Marco Barbanti et al. JACC Cardiovasc Interv. 2020 Nov 9;13(21):2542-2555. doi: 10.1016/j.jcin.2020.07.006.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....